"衛達"胃舒定膜衣錠４００公絲（希每得定）

Riik: Taiwan

keel: hiina

Allikas: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

Toimeaine:

CIMETIDINE

Saadav alates:

衛達化學製藥股份有限公司 台中市工業區２３路２１號 (30950745)

ATC kood:

A02BA01

Ravimvorm:

膜衣錠

Koostis:

CIMETIDINE (5640000500) 400MG

Ühikuid pakis:

瓶裝;;鋁箔盒裝

Klass:

製　劑

Retsepti tüüp:

須由醫師處方使用

Valmistatud:

衛達化學製藥股份有限公司 台中市工業區２３路２１號 TW

Terapeutiline ala:

cimetidine

Näidustused:

胃潰瘍、十二指腸潰瘍及治療病理性分泌過多諸症（如ＺＯＬＬＩＮＧＥＲ－ＥＬＬＩＳＯＮ症

Toote kokkuvõte:

有效日期: 2028/12/22; 英文品名: WEISDIN F.C. TABLETS 400MG "WEIDAR" (CIMETIDINE)

Loa andmise kuupäev:

1986-12-22

Infovoldik

Onlok Film Coated Tablets 400mg
Each film coated tablet contains:
Cimetidine…………..400mg
Therapeutic indications: It is indicated in the treatment of duodenal
and benign
gastric ulceration, including that associated with non-steroidal
anti-inflammatory
agents, recurrent and stomal ulceration, oesophageal reflux disease
and other
conditions where reduction of gastric acid by Onlok film coated
tablets has been
shown to be beneficial: persistent dyspeptic symptoms with or without
ulceration,
particularly meal-related upper abdominal pain, including such
symptoms
associated with non-steroidal anti-inflammatory agents. Onlok film
coated tablets is
also recommended in the management of the Zollinger-Ellison syndrome.
Posology and method of administration:
For oral administration.
The total daily dose by any route should not normally exceed 2.4g(6
tablets)
Adults:
Oral: Take one tablet with breakfast and at bedtime. For patients with
duodenal or
benign gastric ulceration, a single daily dose of 800mg at bedtime is
recommended.
Symptomatic relief is usually rapid. Treatment should be given
initially for at least
four weeks(six weeks in benign gastric ulcer, eight weeks in ulcer
associated with
continued non-steroidal anti-inflammatory agents)even if symptomatic
relief has
been achieved sooner. Most ulcers will have healed by that stage, but
those which
have not will usually do so after a further course of treatment.
Treatment may be continued for longer periods in those patients who
may benefit
from reduction of gastric secretion and the dosage may be reduced as
appropriate
to 400mg at bedtime or 400mg in the morning and bedtime. In patients
with benign
peptic ulcer disease who have responded to the initial course, relapse
may be
prevented by continued treatment, usually with 400mg at bedtime; 400mg
in the
morning and at bedtime has also been used.
In oesophageal reflux disease, 400mg four times a day, with meals and
at bedtime,
for four to eight weeks is recommended to heal oesophagitis and
relieve associated
sym